Investment Research & Advisory Group Inc. Sells 775 Shares of IQVIA Holdings Inc. $IQV

Investment Research & Advisory Group Inc. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,202 shares of the medical research company’s stock after selling 775 shares during the quarter. Investment Research & Advisory Group Inc.’s holdings in IQVIA were worth $2,711,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Smith Salley Wealth Management grew its holdings in shares of IQVIA by 6.4% in the second quarter. Smith Salley Wealth Management now owns 12,311 shares of the medical research company’s stock worth $1,940,000 after purchasing an additional 739 shares during the last quarter. Addenda Capital Inc. boosted its position in IQVIA by 2.0% during the 2nd quarter. Addenda Capital Inc. now owns 49,232 shares of the medical research company’s stock valued at $7,758,000 after buying an additional 984 shares during the period. Camelot Portfolios LLC bought a new stake in IQVIA in the 2nd quarter worth $553,000. ORG Wealth Partners LLC raised its stake in shares of IQVIA by 73.9% during the second quarter. ORG Wealth Partners LLC now owns 614 shares of the medical research company’s stock valued at $100,000 after acquiring an additional 261 shares during the last quarter. Finally, Signaturefd LLC boosted its holdings in shares of IQVIA by 29.6% during the second quarter. Signaturefd LLC now owns 2,930 shares of the medical research company’s stock worth $462,000 after purchasing an additional 669 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and upped their price target for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Barclays lifted their price target on shares of IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Truist Financial lifted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Finally, Cowen reissued a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $229.64.

IQVIA Trading Up 1.6%

Shares of NYSE:IQV opened at $179.51 on Monday. The stock’s fifty day moving average price is $187.01 and its 200-day moving average price is $167.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $30.52 billion, a P/E ratio of 25.98, a PEG ratio of 1.97 and a beta of 1.32. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $237.34.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. During the same period last year, the firm earned $2.64 EPS. IQVIA’s revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.